Table 1 Patient and treatment details
From: Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Number (%) | ||
|---|---|---|
(n = 215) | ||
Excluded from analysis | 17 | |
Gender | ||
Male | 110 | (56%) |
Female | 88 | (44%) |
Age (median, range) | 67 | (42 - 93) |
Tumour Location | ||
(tumours may involve more than 1 region) | ||
Head | 114 | (58%) |
Head and Body | 27 | (14%) |
Body | 36 | (18%) |
Body and Tail | 3 | (2%) |
Tail | 6 | (3%) |
Head, Body and Tail | 5 | (3%) |
No information | 7 | (4%) |
Radiotherapy | ||
< 50 Gy | 30 | (16%) |
≥ 50 Gy | 160 | (84%) |
Median Dose (range) | 52.2 Gy | (39.6 - 54.4 Gy) |
Previous Chemotherapy | ||
All | 23 | (12%) |
Gemcitabine mono | 11 | (6%) |
Gemcitabine-containing regimen | 8 | (5%) |
Concomitant Chemotherapy | ||
All | 198 | |
Gemcitabine-containing regimen | 198 | (100%) |
Gemcitabine mono | 194 | (97.5%) |
Gemcitabine + 5-FU or Capecitabine | 3 | (1.5%) |
Gemcitabine + Cisplatin | 1 | (0.5%) |
IORT After Tumor Resection | 26 | (51%) (n = 51) |
IORT - Doses | (n = 26) | |
10 Gy | 1 | (4%) |
12 Gy | 4 | (15%) |
15 Gy | 21 | (81%) |